University of Michigan

Mallinckrodt Medical, Inc.

Other

Bayer Corporation

Robert M Strieter

Steven L Kunkel

Leon R Lyle

Peter J Polverini

David M Markovitz

Cory Hogaboam

Nicholas W Lukacs

Elise Brownell

Brian R Lane

Kenneth J Simpson

Cynthia L Bone-Larson

Lisa M Colletti

Disclosed are various discoveries concerning the angiogenic and angiostatic properties of the CXC chemokines, including the finding that the ELR motif controls the ability of these molecules to induce angiogenesis. Aspects of the invention include, for example, the identification of IP-10, MIG and certain IL-8 analogues as angiostatic agents, and their use in inhibiting angiogenesis in various systems.

Treatment of idiopathic pulmonary fibrosis using IP-10

Methods are provided for inhibiting or suppressing viral replication in an infected host cell. More specifically, methods are provided for inhibiting or suppressing viral replication in an infected host cell by administering compounds that interfere with the binding of C-X-C chemokines to C-X-C chemokine receptors. Such methods are advantageous for treating viral infections such as human immunodefeciency virus infections.

Methods for inhibition of HIV replication using a small molecule inhibitor

Disclosed is the surprising discovery that CXC chemokines function to induce rapid hepatocyte proliferation and liver regeneration after injury. The invention thus provides a range of compositions and methods for use in treating liver injury, including those suitable for treating acetaminophen overdose outside the therapeutic window for N-acetyl-cysteine treatment, and those that limit the hepatotoxic side-effects of gene therapy regimens.

Treatment of liver disease and injury with CXC chemokines

CXC chemokines as regulators of angiogenesis

This invention provides pharmaceutical compositions comprising anti-SCF antibodies for the reduction of eosinophila in the lungs of mammals. This invention also provides for methods of treating asthma and generating a murine model for asthma.

Method for treating asthma using SCF antibody

A method of imaging a target site in an animal's body in which a labelled chemokine is introduced into the animal's body and allowed to accumulate at a target site which includes corresponding receptor molecules. The accumulated, labelled chemokine material then is detected so as to image the target site of the body.

Radiolabeled neutrophil activating peptides for imaging

A composition suitable for administration to a warm-blooded animal comprising antisense MCP-1 peptide or oligonucleotide or a molecule capable of interacting with MCP-1 peptide or information for its synthesis which may or may not be labeled with a radionuclide by means of a chelate ligand capable of administration to an animal to produce reliable visual imaging of areas of potential restenosis or to produce therapeutic effects on areas of areas of potential restenosis.

Therapeutic treatment for inhibiting vascular restenosis

A method of imaging a target site in an animal's body in which a labelled CC chemokine or Monocyte Attractant Protein (MCP) material is introduced into the animal's body and allowed to accumulate at a target site which includes MCP receptor molecules. The accumulated, labelled MCP material is then detected so as to image the target site of the body.

Growing community of inventors

Ann Arbor, MI, United States of America

Robert M Strieter